INNATE PHARMA Aktie
| 1,78EUR | 0,01EUR | 0,68% |
WKN DE: A0LCUJ / ISIN: FR0010331421
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 237 | 215 | 210 | 179 | 181 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,24 | 0,06 | 0,24 | 0,29 | 0,07 |
Bilanz (in Mio. EUR) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 173 | 138 | 140 | 148 | 86 |
| Summe Anlagevermögen | 134 | 129 | 68 | 36 | 25 |
| Summe Aktiva | 307 | 267 | 208 | 184 | 111 |
Bilanz (in Mio. EUR) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 151 | 160 | 154 | 132 | 102 |
| Summe Eigenkapital | 156 | 107 | 54 | 52 | 9 |
| Summe Passiva | 307 | 267 | 208 | 184 | 111 |
Adresse
| 117, Avenue de Luminy, 13009 Marseille | |
| Telefon | +33 (4) 30-30-30-30 |
| Internet | http://www.innate-pharma.com |
Management
|
Christian Martin Itin
Director |
|
Claire de Saint Blanquat
Secretary, VP-Legal & Corporate Affairs |
|
Eric Vivier
Chief Scientific Officer & Senior Vice President |
|
Frederic Lombard
Chief Financial Officer & Senior Vice President |
|
Irina Staatz-Granzer
Chairman |
|
Jonathan Dickinson
Chief Executive Officer & Director |
|
Marty J. Duvall
Director |
|
Nicola Beltraminelli
Chief Development Officer & Vice President |
|
Odile Belzunce
Vice President-Compliance & Operations |
|
Odile Laurent
VP-Human Resources & Social Relations |
|
Olivier Martinez
Member-Supervisory Board |
|
Pascale Boissel
Independent Member-Supervisory Board |
|
Sally Bennett
Independent Member-Supervisory Board |
|
Sonia Quaratino
Chief Medical Officer & Executive Vice President |
|
Stephanie Cornen
Vice President-Investor Relations & Communications |
|
Véronique Chabernaud
Independent Member-Supervisory Board |
|
Yannis Morel
Chief Operating Officer & Executive Vice President |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.